Literature DB >> 12605370

Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.

Daniela Massi1, Alessandro Franchi, Sheyda Ketabchi, Milena Paglierani, Nicola Pimpinelli, Marco Santucci.   

Abstract

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have been implicated in the development and progression of many tumors, but data for primary neuroendocrine carcinoma (PNC) of the skin are lacking. The aim of the study was to assess the expression of MMPs and TIMPs in PNC and to evaluate their prognostic significance. Expression of MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, MMP-13, and MMP-14 and TIMP-1, TIMP-2, and TIMP-3 was evaluated by immunohistochemistry on 23 samples of PNC of the skin. The results were matched with clinical features and patient survival. In the 23 specimens of PNC, high (>20% of positive neoplastic cells) MMP-1 expression was found in 13 (56.5%) cases. MMP-2 was evidenced in 12 (52.1%) cases, 8 (34.7%) of which showed high expression in neoplastic cells. MMP-3 was detected in 11 cases (47.8%), with high expression in 9 (39.1%) of them. High MMP-9 expression was observed in 3 (13%) cases, whereas high MMP-14 expression was detected in 11 (47.8%) specimens. Expression of TIMP-1 by neoplastic cells was found in 8 (34.7%) cases, with high expression in 3 cases, whereas high TIMP-3 expression was detected in 21 (91.3%) cases. No immunoreactivity for MMP-11, MMP-13, or TIMP-2 was found. Statistical analysis failed to identify a significant correlation between MMP/TIMP expression and clinical parameters. By univariate analysis, stage >I (P = 0.01), high expression of MMP-1 (P = 0.04) and MMP-3 (P = 0.01) resulted significant negative prognostic factors, whereas by multivariate analysis, stage was the only factor that affected survival (P = 0.02). Our results suggest that MMP-1 and MMP-3 may influence the invasive and metastatic potential of PNCs. It is conceivable that future attempts to specifically block MMP-1 and MMP-3 activity may provide a novel means to inhibit invasiveness and distant spread in selected patients with PNC. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12605370     DOI: 10.1053/hupa.2003.51

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  14 in total

1.  Characterization of anti-TIMP-1 monoclonal antibodies for immunohistochemical localization in formalin-fixed, paraffin-embedded tissue.

Authors:  Irene Vejgaard Sorensen; Claus Fenger; Henrik Winther; Niels T Foged; Ulrik Lademann; Nils Brünner; Pernille A Usher
Journal:  J Histochem Cytochem       Date:  2006-03-03       Impact factor: 2.479

2.  Effects of 17 beta-estradiol on the expression of interstitial collagenases-8 and -13 (MMP-8 and MMP-13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in ovariectomized rat osteoblastic cells.

Authors:  Jian Li; Er-Yuan Liao; Ru-Chun Dai; Qi-You Wei; Xiang-Hang Luo
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

Review 3.  [The heart in cases of viral, bacterial and parasitic infections].

Authors:  B Maisch; P Alter; K Karatolius; V Ruppert; S Pankuweit
Journal:  Internist (Berl)       Date:  2007-03       Impact factor: 0.743

4.  DNA ploidy analysis and expression of MMP-9, TIMP-2, and E-cadherin in gastric carcinoma.

Authors:  Jing-Fang Zhang; Yuan-Ping Zhang; Feng-Yun Hao; Cai-Xin Zhang; Yu-Jun Li; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2005-09-28       Impact factor: 5.742

5.  Expression of MT-1 MMP, MMP2, MMP9 and TIMP2 mRNAs in ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Hee Jung Kim; Chan-il Park; Byeong Woo Park; Hy-de Lee; Woo Hee Jung
Journal:  Yonsei Med J       Date:  2006-06-30       Impact factor: 2.759

Review 6.  [Classification, genetic predisposition and risk factors for the development of cardiomyopathies].

Authors:  S Pankuweit; A Richter; V Ruppert; R Funck; B Maisch
Journal:  Internist (Berl)       Date:  2008-04       Impact factor: 0.743

7.  Expression of MMP-10, MMP-21, MMP-26, and MMP-28 in Merkel cell carcinoma.

Authors:  Sari Suomela; Virve Koljonen; Tiina Skoog; Heli Kukko; Tom Böhling; Ulpu Saarialho-Kere
Journal:  Virchows Arch       Date:  2009-11-17       Impact factor: 4.064

8.  Low expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in glioblastoma predicts longer patient survival.

Authors:  Charlotte Aaberg-Jessen; Karina Christensen; Hanne Offenberg; Annette Bartels; Tanja Dreehsen; Steinbjørn Hansen; Henrik Daa Schrøder; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

9.  Letter regarding "MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies" by Wu KP et al.

Authors:  Chao Tu; Jianping Zhou; Lianwen Yuan
Journal:  Tumour Biol       Date:  2016-01-27

10.  MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies.

Authors:  Kun-Peng Wu; Qiang Li; Fu-Xiang Lin; Jun Li; Lu-Min Wu; Wei Li; Qiao-Zhu Yang
Journal:  Tumour Biol       Date:  2014-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.